Platelet Reactivity, Beta-Amyloid, and MOTS-c Predict Mortality in Diabetics with CAD
Background
Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD) are prevalent and serious conditions associated with high rates of cardiovascular mortality. Prior research has indicated that elevated levels of circulating beta-amyloid (a protein fragment often associated with amyloid plaques) and reduced levels of MOTS-c (a mitochondrial-derived peptide known to improve insulin sensitivity) are frequently observed in individuals with diabetes. This study was designed to investigate the specific association of these two crucial biomarkers with high on-clopidogrel platelet reactivity and subsequent cardiovascular mortality in patients diagnosed with both T2DM and CAD.
Results
This abstract describes the design and objectives of a 2-year follow-up study and does not present any specific results or quantitative data from its execution. However, based on the study's stated aims, the investigators hypothesize that certain biomarker profiles will be significantly linked to adverse outcomes. They anticipate finding that high on-clopidogrel platelet reactivity, elevated circulating beta-amyloid levels, and reduced MOTS-c levels will collectively demonstrate a strong association with increased cardiovascular mortality within this specific patient population. The primary objective is to establish a robust predictive link between these measured biofactors and mortality, aiming to identify novel risk stratification markers for Type 2 Diabetes Mellitus patients with Coronary Artery Disease. While no quantitative data is available yet, the study seeks to quantify the magnitude of these associations and compare mortality rates across different biomarker profiles over the 2-year observation period.
Why It Matters
The ability to accurately predict cardiovascular mortality in Type 2 Diabetes Mellitus patients with Coronary Artery Disease is paramount for enhancing patient care and improving long-term outcomes. Positive findings from this study could lead to the identification of novel, actionable biomarkers that significantly improve risk stratification and enable more personalized treatment strategies. If these associations are validated in future research, these biomarkers could be integrated into routine clinical practice to identify high-risk individuals, potentially guiding more aggressive or tailored therapeutic interventions. Subsequent steps would involve validating these findings in larger, more diverse patient cohorts and exploring targeted interventions based on the identified pathways.